Letrozol Ratiopharm

Letrozole, the active ingredient in Letrozol Ratiopharm, is an aromatase inhibitor presented as an oral tablet for oral use. It reduces estrogen production and is employed in the treatment of hormone receptor‑positive breast cancer in postmenopausal women, both as adjuvant therapy and for advanced disease.

GNH USA supplies Letrozol Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide. All batches are manufactured under EU GMP standards and undergo rigorous quality testing before distribution, ensuring consistent potency and safety for patients.

Letrozole is used in the management of estrogen‑dependent breast cancer, targeting tumors that rely on peripheral estrogen synthesis.

- Hormone receptor‑positive breast cancer in postmenopausal women: Administered as adjuvant therapy to lower recurrence and improve disease‑free survival. - Early‑stage breast cancer: Used after surgery to reduce the risk of progression and support long‑term remission. - Advanced or metastatic breast cancer: Employed to control tumor growth and extend survival in patients with estrogen‑driven disease.

Letrozole may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Hot flashes: sudden feeling of warmth, often with sweating. - Joint or muscle pain: aches in bones, joints, or muscles. - Fatigue: persistent tiredness or lack of energy. - Nausea: feeling of queasiness or urge to vomit. - Headache: mild to moderate head pain. - Sweating: increased perspiration.

Serious or Rare Side Effects: - Severe osteoporosis or bone fractures: significant loss of bone density leading to fractures. - Deep vein thrombosis or pulmonary embolism: blood clots in veins or lungs. - Liver function abnormalities: elevated enzymes indicating hepatic stress.

When prescribing Letrozole, clinicians should consider several precautionary measures to ensure patient safety. - Bone health monitoring: assess bone mineral density and consider calcium/vitamin D supplementation. - Cardiovascular risk assessment: evaluate history of thromboembolic events before initiating therapy. - Liver function testing: perform baseline and periodic liver enzyme tests. - Drug interactions: review concomitant medications that may affect estrogen levels. - Pregnancy and lactation: contraindicated; avoid use in pregnant or breastfeeding women. - Store at ambient temperature: keep tablets in original container, protect from moisture and light.

Letrozole can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce plasma concentrations. - Estrogen‑containing therapies (e.g., hormone replacement therapy): antagonize therapeutic effect.

Moderate Interactions (Monitor Closely): - Antifungal agents (e.g., ketoconazole): may increase exposure. - Anticoagulants (e.g., warfarin): potential for altered INR, monitor coagulation. - Selective serotonin reuptake inhibitors (e.g., fluoxetine): may affect metabolism.